Preclinical efficacy of anecortave acetate

Anecortave acetate is a unique ocular angiostatic cortisene that has broad-based anti-angiogenic activity in 14 different preclinical models of neovascularization, across multiple species and inducers of neovascularization. Anecortave acetate is being tested clinically for inhibition of choroidal neovascularization associated with age-related macular degeneration.